Literature DB >> 10686392

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

T Tapiola1, T Pirttilä, M Mikkonen, P D Mehta, I Alafuzoff, K Koivisto, H Soininen.   

Abstract

Earlier studies have shown elevated levels of tau protein and decreased levels of amyloid beta42 in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). We investigated the concentrations of Abeta42, Abeta40 and tau in CSF from AD patients on the baseline and after follow-up period of 3 years using ELISA assays. There was a significant decrease of Abeta42 (P<0.05) and Abeta40 (P<0.05) levels with time. AD patients with the duration of the disease 2 years or less at baseline had more pronounced decrease of Abeta42 concentrations compared to those with the duration of the disease more than 2 years at baseline (P<0.05). CSF tau protein concentrations increased in 9/17 but decreased in 8/17 patients. These results suggest that Abeta42 and Abeta40 may be useful in monitoring the long-term progression of AD particularly in the early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686392     DOI: 10.1016/s0304-3940(00)00767-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  24 in total

Review 1.  Blood-based diagnostics of traumatic brain injuries.

Authors:  Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

2.  The choroid plexus removes beta-amyloid from brain cerebrospinal fluid.

Authors:  Janelle S Crossgrove; G Jane Li; Wei Zheng
Journal:  Exp Biol Med (Maywood)       Date:  2005-11

Review 3.  Laboratory biomarkers in Alzheimer's disease.

Authors:  Joshua R Steinerman; Lawrence S Honig
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

4.  Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.

Authors:  Timo Grimmer; Matthias Riemenschneider; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Tohru Shiga; Hans-Jürgen Wester; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

Review 5.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Longitudinal change of biomarkers in cognitive decline.

Authors:  Raymond Y Lo; Alan E Hubbard; Leslie M Shaw; John Q Trojanowski; Ronald C Petersen; Paul S Aisen; Michael W Weiner; William J Jagust
Journal:  Arch Neurol       Date:  2011-06-13

Review 7.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

Review 8.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 9.  Beta-amyloid deposition and the aging brain.

Authors:  Karen M Rodrigue; Kristen M Kennedy; Denise C Park
Journal:  Neuropsychol Rev       Date:  2009-11-12       Impact factor: 7.444

10.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.

Authors:  Rachel Mistur; Lisa Mosconi; Susan De Santi; Marla Guzman; Yi Li; Wai Tsui; Mony J de Leon
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.